{"id":"recombinant-human-tissue-plasminogen-activator","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (intracranial hemorrhage)"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1201718","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rtPA is a serine protease that binds to fibrin in blood clots and catalyzes the conversion of plasminogen to plasmin, a potent fibrinolytic enzyme. Plasmin then degrades the fibrin matrix of the clot, leading to thrombolysis and restoration of blood flow. This mechanism makes it effective for acute thrombotic conditions where rapid clot dissolution is critical.","oneSentence":"Recombinant human tissue plasminogen activator (rtPA) converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:19.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute myocardial infarction"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT05065216","phase":"PHASE2, PHASE3","title":"Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","status":"RECRUITING","sponsor":"DiaMedica Therapeutics Inc","startDate":"2021-11-07","conditions":"Acute Stroke, Ischemic Stroke, Stroke","enrollment":728},{"nctId":"NCT07302854","phase":"PHASE2, PHASE3","title":"Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2025-12-30","conditions":"Acute Ischemic Stroke, Medium Vessel Occlusion","enrollment":382},{"nctId":"NCT06184321","phase":"EARLY_PHASE1","title":"Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":30},{"nctId":"NCT07201688","phase":"PHASE3","title":"Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.","status":"RECRUITING","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-30","conditions":"Acute Ischemic Stroke","enrollment":890},{"nctId":"NCT05752916","phase":"PHASE4","title":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-06-02","conditions":"Acute Ischemic Stroke","enrollment":570},{"nctId":"NCT06769256","phase":"PHASE4","title":"Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden","status":"RECRUITING","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2025-01-01","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":300},{"nctId":"NCT05700591","phase":"PHASE3","title":"rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2023-01-29","conditions":"Acute Ischemic Stroke","enrollment":1552},{"nctId":"NCT05624190","phase":"PHASE4","title":"Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-16","conditions":"Ischemic Stroke, Acute","enrollment":256},{"nctId":"NCT05295173","phase":"PHASE3","title":"A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）","status":"COMPLETED","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2022-03-21","conditions":"Acute Ischemic Stroke","enrollment":1412},{"nctId":"NCT04797013","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2021-06-12","conditions":"Acute Ischemic Stroke","enrollment":1430},{"nctId":"NCT02835534","phase":"PHASE4","title":"The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI","status":"COMPLETED","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2016-05","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":818},{"nctId":"NCT03108833","phase":"PHASE2","title":"A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2017-06-06","conditions":"Acute Pulmonary Embolism","enrollment":108},{"nctId":"NCT03468933","phase":"PHASE4","title":"Fibrinolysis Compared to Thoracoscopy for Pleural Infection","status":"COMPLETED","sponsor":"Tulane University","startDate":"2017-11-01","conditions":"Pleural Infection, Empyema, Pleural Diseases","enrollment":32},{"nctId":"NCT04676659","phase":"PHASE2","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2018-05-12","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT01429350","phase":"PHASE4","title":"Assess the Penumbra System in the Treatment of Acute Stroke","status":"COMPLETED","sponsor":"Penumbra Inc.","startDate":"2012-05","conditions":"Ischemic Stroke","enrollment":108},{"nctId":"NCT03541668","phase":"PHASE3","title":"Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-05-18","conditions":"Acute Ischaemic Stroke","enrollment":674},{"nctId":"NCT02973139","phase":"NA","title":"Fibrinolysis Compared to Thoracoscopy for Pleural Infection","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-07-14","conditions":"Pleural Infection, Pleural Diseases","enrollment":32},{"nctId":"NCT04110275","phase":"PHASE2","title":"Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2019-10","conditions":"Acute Pulmonary Embolism","enrollment":174},{"nctId":"NCT04028518","phase":"PHASE2","title":"A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2019-07-20","conditions":"Acute Ischemic Stroke","enrollment":180},{"nctId":"NCT01657461","phase":"NA","title":"Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial","status":"COMPLETED","sponsor":"Medtronic Neurovascular Clinical Affairs","startDate":"2012-12","conditions":"Acute Ischemic Stroke","enrollment":196},{"nctId":"NCT02347358","phase":"PHASE2","title":"Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"The Second Artillery General Hospital","startDate":"2015-02","conditions":"Ischemic Cerebrovascular Accident","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alteplase","brand name: Actilyse","rt-PA"],"phase":"phase_3","status":"active","brandName":"Recombinant human tissue plasminogen activator","genericName":"Recombinant human tissue plasminogen activator","companyName":"Angde Biotech Pharmaceutical Co., Ltd.","companyId":"angde-biotech-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human tissue plasminogen activator (rt-PA) is used to treat conditions such as acute ischemic stroke, acute ST elevation myocardial infarction, medium vessel occlusion, and acute pulmonary embolism. It works as a hyaluronic acid hydrolytic enzyme, breaking down hyaluronic acid, which is a type of enzyme modality.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}